Celldex Therapeutics, Inc. (CLDX), Dendreon Corporation (DNDN): A Promising Platform for Cancer Immunotherapy

Page 2 of 2

The breast cancer treatment CDX-011 has also showed impressive results in the EMERGE Phase 2 trial.  This drug uses a slightly different mechanism licensed from Seattle Genetics, Inc. (NASDAQ:SGEN), and directly targets a variant of breast cancer that is currently difficult to treat.

Steinman’s Legacy

The approaches of both Celldex Therapeutics, Inc. (NASDAQ:CLDX) and Dendreon Corporation (NASDAQ:DNDN) stem from Steinman’s work.  FDA approval of Provenge was very exciting and the clinical data is quite impressive, yet its sky-high cost has prevented it from meeting investor expectations.  Sales growth has stalled for the last five quarters at around $80 million, and the stock hasn’t fared well either.

Celldex, on the other hand, has soared 90% YTD on strong clinical trial data and a robust pipeline.  Celldex may face competition in the immunotherapy space from Bristol Myers Squibb Co. (NYSE:BMY)‘s PD-1 inhibitor Nivolumab, which Citigroup Inc (NYSE:C) estimates will bring in a massive $7 billion annually.  It is also possible that any marketed treatment from Celldex could work synergistically with Nivolumab, as the two treatments target different biochemical pathways.

Celldex Therapeutics, Inc. (NASDAQ:CLDX)’ promise isn’t limited to cancer vaccines.  The proprietary APC targeting platform provides an abundance of possible treatment courses, and Celldex has only begun to scratch the surface.  Antibodies targeted to APCs can also be conjugated to immunomodulators for immunosuppression in allergic reaction, inflammation, organ transplant, or autoimmune disorders (including an HIV vaccine in Phase 1 trials).  Celldex also obtained rights from Amgen, Inc. (NASDAQ:AMGN) for a potent immunostimulant, now called CDX-301.

Bottom line

With a $114 million capital raise and $16 million cash burn in the first quarter, Celldex has plenty of fuel to carry it through rindopepimut and CDX-011 trials and continue preclinical investigation of other immunotherapy applications.  I also anticipate some pretty lucrative partnerships, as Celldex is openly shopping for commercialization and R&D partners.


Seth Robey has no position in any stocks mentioned. The Motley Fool owns shares of Dendreon.
Seth is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

The article A Promising Platform for Cancer Immunotherapy originally appeared on Fool.com is written by Seth Robey.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2